What’s New in Heart Failure? Highlights and Insights from ESC 2025

NEW late breaking trials in heart failure (HF) continue to refine therapy in patients with heart failure with reduced ejection fraction (HFrEF) and post-myocardial infarction (MI). DIGIT-HF,1 BETAMI-DANBLOCK,2 REBOOT-CNIC,3 VICTOR,4 and DAPA ACT HF-TIMI 685 are some studies presenting novel evidence on pharmacological therapy optimisation, including digitoxin, β-blockers, vericiguat, and sodium glucose co-transporter-2 (SGLT2) inhibitors. These studies highlight the strategic use of traditional and innovative therapies, taking patient-specific traits, comorbidities, and time of intervention into account. Interpretation of these studies proves critical for optimisation of benefits and guiding patient-specific HF management.